Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Clinical Drug Investigation

Volumn 29, Issue 3, 2009, Pages 173-184

  Lenox Smith, Alan ^a,c   Greenstreet, Liz ^a   Burslem, Kate ^a   Knight, Chris ^b  

^a Medical Department   (United Kingdom)

^b Heron Evidence Development Ltd   (United Kingdom)

^c Wyeth Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; LITHIUM; MIRTAZAPINE; VENLAFAXINE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DELPHI STUDY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULARY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; REMISSION; RESOURCE ALLOCATION; SUSTAINED DRUG RELEASE; TABLET; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DECISION TREES; DELPHI TECHNIQUE; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; DRUGS, GENERIC; FLUOXETINE; GREAT BRITAIN; HUMANS; PSYCHIATRIC STATUS RATING SCALES; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 61349198117     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929030-00004     Document Type: Article

References (31)

1. Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity Surveys of Great Britain: initial findings from the household survey. Psychol Med 1997; 27: 775-89
2. Lepine J-P, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan European study - EPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12: 19-29
3. Thomas CM, Morris S. Cost of depression amongst adults in England in 2000. Br J Psychiatry 2003; 183: 311-9
4. Depression (amended). Management of depression in primary and secondary care. NICE Clinical Guideline 23 (amended): April 2007 [online]. Available from URL: http://www.nice.org.uk [Accessed 2009 Feb 1]
5. Anderson IM, Nutt DJ, Deakin JFW, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines. J Psychopharmacol 2000; 14 (1): 3-20
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
7. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5: 115-20
8. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396-404
9. Lenox-Smith A, Conway P, Knight C, et al. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. PharmacoEconomics 2004; 22 (5): 311-9
10. Trivedi MH, Wan GJ, Mallick R, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol 2004; 24: 497-506
11. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for depression in primary care practice. Arch Gen Psychiatry 1998; 55 (7): 645-51
12. Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors and placebo. J Clin Psychiatry 2003; 64 (3): 321-30
13. NHS reference costs 2005-06, Department of Health, Accessed by: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884
14. Curtis L, Netten A. Unit costs of health & social care 2005. Canterbury. Personal Social Services Research unit
15. Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J of Psychiatry 1996; 168:768-71
16. NICE Guidance Electroconvulsive therapy (ECT) (No. 59) 2003 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/59ectfullguidance.pdf [Accessed 2009 Feb 1]
17. Netten A, Curtis L. Unit costs of health & social care 2003. Canterbury. Personal Social Services Research unit
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised: DSM-III-R. Washington, DC: American Psychiatric Association, 1987
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., revised: DSM-IV-R. Washington, DC: American Psychiatric Association, 2000
20. Nemeroff C, Cantillon M. A comparison of venlafaxine versus fluoxetine or placebo in depressed outpatients. Poster presented at CINP, Brussels, 2000
21. Schatzberg A, Cantillon M. Antidepressant early response and remission with venlafaxine or fluoxetine in depressed geriatric outpatients. Poster presented at CINP, Brussels, 2000
22. Rudolph R, Feiger A. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56: 171-81
23. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiat 1996; 20: 57-71
24. Silverstone PH, Entsuah R, Hackett D, et al. Once-daily venlafaxine extended-release (XR) compared with fluoxetine and outpatients with depression and anxiety. J Clin Psychiatry 1999; 60: 22-8
25. Rudolph R. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Hamburg: poster presented at World Congress of Psychiatry; 1999
26. Kornaat H. Randomised, double-blind comparison of venlafaxine and fluoxetine for moderately depressed outpatients. Poster presented at CINP 1997
27. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Psychiatry 1997; 3: 51-58
28. Alves C, Cachola I, Brandao J, et al. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 1999; 5 (2): 57-63
29. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59: 352-7
30. Stevens I. Comparison of the efficacy and safety of venlafaxine and fluoxetine in GP patients with moderate to severe depression. Poster presented at World Congress of Biological Psychiatry 1997
31. Ian Anderson. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58 (1): 19-36